Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
15 août 2022 07h00 HE
|
Clene Inc.
Topline results from the Phase 2 VISIONARY-MS clinical trial with CNM-Au8® met the primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional...
Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
27 juin 2022 07h00 HE
|
Clene Inc.
SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Ferrer Brings ALSton the Dragon to Life to Raise Awareness of ALS
21 juin 2022 04h00 HE
|
Ferrer
BARCELONA, Spain, June 21, 2022 (GLOBE NEWSWIRE) -- On Global Amyotrophic Lateral Sclerosis / Motor Neuron Disease (ALS/MND) Awareness Day on June 21, the Phantasticals campaign, run by Ferrer, the...
PathMaker Neurosystems Receives $100,000 START Award from MassVentures
08 juin 2022 07h00 HE
|
PathMaker Neurosystems Inc.
BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
AB Science annonce que Health Canada a démarré la revue du dossier d’enregistrement du masitinib dans le traitement de la SLA
26 mai 2022 16h46 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE HEALTH CANADA A DEMARRE LA REVUE DU DOSSIER D’ENREGISTREMENT DU MASITINIB DANS LE TRAITEMENT DE LA SCLEROSE LATERALE AMYOTROPHIQUE (SLA), SUITE A L’EXAMEN...
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
26 mai 2022 16h46 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS STARTED THE REVIEW OF NEW DRUG SUBMISSION FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS), FOLLOWING ISSUANCE OF...
AB Science annonce avoir reçu l'autorisation de Health Canada pour soumettre une demande de mise sur le marché du masitinib dans le traitement de la SLA sous le statut NOC/c (Notice of Compliance with Conditions)
21 févr. 2022 11h48 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR RECU L’AUTORISATION DE HEALTH CANADA POUR SOUMETTRE UNE DEMANDE DE MISE SUR LE MARCHE DU MASITINIB DANS LE TRAITEMENT DE LA SCLEROSE LATERALE...
AB Science announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy
21 févr. 2022 11h48 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED AUTHORIZATION TO FILE A NEW DRUG SUBMISSION FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) UNDER THE NOTICE OF...
AB Science présentera son programme de développement dans la Sclérose Latérale Amyotrophique (SLA) lors de l’édition 2022 du ALS Drug Development Summit
07 févr. 2022 12h12 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTERA SON PROGRAMME DE DÉVELOPPEMENT DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) LORS DE L’ÉDITION 2022 DU ALS DRUG DEVELOPMENT SUMMIT Paris, 7 février 2022,...
AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit
07 févr. 2022 12h12 HE
|
AB Science
PRESS RELEASE AB SCIENCE TO PRESENT ON ITS AMYOTROPHIC LATERAL SCLEROSIS (ALS) DEVELOPMENT PROGRAM AT THE 2022 ALS DRUG DEVELOPMENT SUMMIT Paris, 07 February, 2022, 6pm CET AB Science SA (Euronext...